CEL and chronic myelogenous leukemia, BCR-ABL1 positive: As shown in Figure S4, AGEs scores, and serum CEL, CML, and MG‐H1 concentrations were statistically different across the CKM syndrome stage transition groups over the three‐year follow‐up period (2019–2022).